<DOC>
	<DOCNO>NCT01867775</DOCNO>
	<brief_summary>The purpose study determine whether mirtazapine effective treatment sleep disorder Alzheimers disease .</brief_summary>
	<brief_title>Mirtazapine Sleep Disorders Alzheimer 's Disease</brief_title>
	<detailed_description>Mirtazapine use depress elderly sleep disorder good tolerability efficacy . The study hypothesis mirtazapine could also use demented sleep disorder . Sleep disorder ( SD ) affect 35 50 percent patient Alzheimer Disease ( AD ) . These disorder often make care patient home difficult It 's also associate high risk institutionalization increase health care cost . Treatment SD people dementia may benefit patient caregiver . However , little known efficacy pharmacological treatment treat sleep disturbance AD .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>Fiftyfive year age old ; Diagnosis probable Alzheimer 's disease National Institute Neurological Communicative Disorders Stroke/the Alzheimer 's Disease Related Disorders Association criterion ; Hachinski Ischemia Scale score le 5 MiniMental State Examination score O 26 Actigraph evidence mean time immobile le 7 hour per night base least 7 night complete actigraph data collect single week ; Forweek history sleep disorder behavior , occur least weekly , report caregiver use Neuropsychiatric Inventory ( NPI ) Nighttime Behavior scale ; Sleep disturbance observe present diagnosis AD ; Other comorbidities , especially delirium , depression , chronic pain medication use may present , cooperate primary symptom ; Computed tomography magnetic resonance imaging since onset memory problem show 1 lacunar infarct nonstrategic area clinical event suggestive stroke intracranial disease normal ; Stable medication 4 week prior screen visit ; Having mobile upper extremity attach actigraph ; Residing responsible spouse , family member , professional caregiver present night would agree assume role principal caregiver 3week protocol ; Ability ingest oral medication participate schedule evaluation Sleep disturbance associate acute illness , delirium psychiatric disease ; Clinically significant movement disorder , akinesia , would affect actigraphic differentiation sleep wakefulness Severe agitation ; Unstable medical condition ; Discontinuation psychotropic sleep medication within 2 week screen visit ; Patient unwilling maintain caffeine abstinence 2:00 PM duration protocol ; Patient unwilling comply maximum limit 2 alcoholic drink per day , 1 alcoholic drink 6:00 PM duration protocol ; Prior use mirtazapine treatment sleep disturbance ; Caregiver deem unreliable supervise wear actigraph , administer trazodone proper time , maintain tbe sleep diary , bring patient schedule visit ;</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Sleep disorder</keyword>
	<keyword>Mirtazapine</keyword>
	<keyword>Treatment</keyword>
	<keyword>Intervention</keyword>
	<keyword>insomnia</keyword>
</DOC>